iGlarLixi: A Fixed-Ratio Combination of Insulin Glargine 100 U/mL and Lixisenatide for the Treatment of Type 2 Diabetes.

about

Adding prandial GLP-1 receptor agonists to basal insulin: a promising option for type 2 diabetes therapy.

P2860

Q52536332-7C1B94CE-017A-4907-9C88-61FD0BB6FF28

P2860

iGlarLixi: A Fixed-Ratio Combination of Insulin Glargine 100 U/mL and Lixisenatide for the Treatment of Type 2 Diabetes.

Item

http://www.wikidata.org/entity/Q38711727

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

iGlarLixi: A Fixed-Ratio Combi ...... Treatment of Type 2 Diabetes.

@en

type

Item

label

iGlarLixi: A Fixed-Ratio Combi ...... Treatment of Type 2 Diabetes.

@en

prefLabel

iGlarLixi: A Fixed-Ratio Combi ...... Treatment of Type 2 Diabetes.

@en

P1476

iGlarLixi: A Fixed-Ratio Combi ...... e Treatment of Type 2 Diabetes

@en

P2093

Jennifer M Trujillo

http://www.w3.org/2001/XMLSchema#string

P2860

Combining incretin-based therapies with insulin: realizing the potential in type 2 diabetes

Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes

10-year follow-up of intensive glucose control in type 2 diabetes

Lixisenatide resensitizes the insulin-secretory response to intravenous glucose challenge in people with type 2 diabetes--a study in both people with type 2 diabetes and healthy subjects.

Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.

Lixisenatide reduces postprandial hyperglycaemia via gastrostatic and insulinotropic effects.

Persistent Effects of Intensive Glycemic Control on Retinopathy in Type 2 Diabetes in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Follow-On Study

Adding once-daily lixisenatide for type 2 diabetes inadequately controlled with newly initiated and continuously titrated basal insulin glargine: a 24-week, randomized, placebo-controlled study (GetGoal-Duo 1).

Adding once-daily lixisenatide for type 2 diabetes inadequately controlled by established basal insulin: a 24-week, randomized, placebo-controlled comparison (GetGoal-L)

Clinical inertia in people with type 2 diabetes: a retrospective cohort study of more than 80,000 people

P304

990-999

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/1060028017717281

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Jennifer Goldman

P577

2017-06-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28645216

http://www.w3.org/2001/XMLSchema#string

P921

type-2 diabetes

iGlarLixi: A Fixed-Ratio Combination of Insulin Glargine 100 U/mL and Lixisenatide for the Treatment of Type 2 Diabetes.

about

P2860

P2860

iGlarLixi: A Fixed-Ratio Combination of Insulin Glargine 100 U/mL and Lixisenatide for the Treatment of Type 2 Diabetes.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P921